11 – 20 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
(
- Contribution to journal › Published meeting abstract
-
Mark
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
(
- Contribution to journal › Published meeting abstract
-
Mark
Expression of P53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5Q)
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0257-0257(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long Term Efficacy And Tolerability Of Anagrelide In Myeloproliferative Disorders
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0746-0746(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
The molecular signature of MDS stem cells supports a stem-cell origin of 5q - myelodysplastic syndromes
(
- Contribution to journal › Article
-
Mark
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
(
- Contribution to journal › Article
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
- 2005
-
Mark
IFN-{gamma} Negatively Modulates Self-Renewal of Repopulating Human Hemopoietic Stem Cells.
(
- Contribution to journal › Article
-
Mark
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
(
- Contribution to journal › Article
- 2004
-
Mark
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
(
- Contribution to journal › Article